Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evexomostat (SDX-7320) + Eribulin in Metastatic TNBC with Metabolic Dysfunction
NCT05570253Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2022
- Primary completion
- Oct 2027
- Modality
- Polymer-based Nanoparticles, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of evexomostat in triple-negative breast cancer (TNBC), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2022; status: recruiting.
02
Drugs
evexomostat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05570253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570253.